皮肤科药物市场－全球产业规模、份额、趋势、机会和预测：治疗方法、类型、给药途径、药物类别、分销管道、地区和竞争格局划分，2021-2031年

全球皮肤病药物市场预计将从 2025 年的 220.2 亿美元成长到 2031 年的 385.2 亿美元，复合年增长率为 9.77%。

此细分市场包括用于诊断和治疗皮肤、毛髮和指甲疾病的药物製剂，涵盖外用、口服和注射。市场成长的主要驱动因素是慢性皮肤病（如干癣和异位性皮肤炎）发病率的上升，以及人口老化导致老年人更容易患皮肤病。例如，美国国家湿疹协会报告称，到2025年，超过10%的美国人口将被诊断出患有某种形式的湿疹，这凸显了有效治疗性介入的重要性以及全球市场的扩张趋势。

儘管前景乐观，但由于先进生物疗法和新型小分子药物的高成本，市场仍面临许多障碍。高昂的价格往往导致患者难以获得治疗和报销，尤其是在医疗预算紧张的发展中地区。此外，新化学实体药物严格的监管核准通讯协定可能会延迟其上市时间并增加研发成本。因此，这些财务和监管障碍可能会阻碍创新治疗方法的广泛应用，并对整个产业的扩张构成严重阻碍。

市场驱动因素

全球慢性及急性皮肤病患病率的不断上升是推动市场成长的主要因素，也因此需要更多药物介入。从自体免疫疾病到皮肤恶性肿瘤，各种疾病的诊断率不断攀升，迫使医疗系统优先考虑有效治疗方法。根据美国癌症协会于2024年1月发布的《2024年癌症事实与数据》，预计当年美国将新增100,640例侵袭性黑色素瘤病例。日益加重的疾病负担与肿瘤相关皮肤科药物处方量的增加直接相关，从而推动了对创新治疗方法的持续需求，以有效满足患者的复杂需求。

同时，生物製药、小分子药物和标靶治疗的进步，凭藉其优于传统全身性治疗的疗效和安全性，正在重塑市场竞争格局。製药公司正积极拓展产品组合，开发具有全新作用机制的药物，尤其针对异位性皮肤炎等难治性疾病。根据赛诺菲于2024年2月发布的“2023财年全年业绩报告”，其用于治疗异位性皮肤炎的生物製药Dupixent的销售额达到107.6亿欧元，这主要得益于患者需求的强劲增长。此外，美容领域的成长也为该行业提供了支撑。艾伯维在2024年发布的预测显示，其2023财年肉毒桿菌素（Botox Cosmetic）的全球净销售额将达到26.8亿美元，这证实了美容皮肤科是整体市场估值的重要组成部分。

市场挑战

先进生物製药和新型小分子药物的高昂成本对全球皮肤病药物市场的扩张构成重大挑战。这些创新治疗方法的巨额价格往往超出医疗预算的承受能力，迫使支付方实施严格的报销限制，例如阶梯疗法和事先核准。这些成本控制措施严重阻碍了患者获得治疗，导致很大一部分合格的患者无法获得处方治疗。缺乏健保覆盖减缓了这些高价值药物的普及速度，直接限制了生产商的收入成长，并阻碍了整个产业的财务发展。

近期产业数据显示，生物製药处方笺保险公司延迟或拒付。如此高的拒付率严重限制了先进疗法的市场渗透率。因此，市场无法有效地将这些昂贵但有效的药物提供给患者，这严重阻碍了整个产业的成长。

市场趋势

人工智慧的融合正在从根本上改变皮肤病学领域的药物研发格局。製药公司正积极利用生成式人工智慧模型来识别药物标靶并优化分子设计，从而显着缩短新治疗方法商业化所需的时间和资金投入。这种技术变革对于复杂的皮肤疾病尤其重要，因为传统的筛检方法难以找到有效的候选药物。例如，在2024年1月题为「Almirall宣布与微软建立合作伙伴关係」的新闻稿中，Almirall宣布了一项为期三年的策略合作，该合作将充分利用生成式人工智慧和先进的分析技术，加速医学皮肤病学领域创新治疗方法的发现和开发。

同时， Janus激酶（JAK）抑制剂正迅速崛起，成为治疗免疫介导性皮肤疾病（如白斑和异位性皮肤炎）领域亟待解决的重大治疗层级。与广谱免疫抑制剂不同，这些小分子药物针对细胞激素通路，对可能对生物製药无反应的患者俱有高效疗效。这些药物的商业性成功表明，它们正日益被寻求非类固醇替代疗法治疗慢性疾病的医生和患者所接受。根据Incyte公司于2024年10月发布的“2024年第三季财务业绩”，外用JAK抑制剂Opzelula的净产品销售额在第三季度达到1.39亿美元，同比增长52%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球皮肤科药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 治疗类型（痤疮、干癣、酒糟、脱髮症、其他）
  • 依类型（处方药、非处方药）
  • 依给药途径（局部用药、口服、注射）
  • 依药物类别（皮质类固醇、类视色素、抗生素、抗真菌药物、Calcineurin抑制剂、其他）
  • 按分销管道（医院药房、零售药房、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美皮肤科药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲皮肤科药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区皮肤科药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲皮肤科药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲皮肤科药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球皮肤科药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• AbbVie Inc.
• Pfizer Inc.
• Glaxo Smith Kline PLC
• Sun Pharmaceutical Industries Ltd
• Galderma SA
• Amgen Inc
• Johnson & Johnson Services, Inc.
• Novartis AG
• Almirall, SA
• Eli Lilly and Company
• Bausch Health Companies Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Dermatological Drugs Market is projected to expand from USD 22.02 billion in 2025 to USD 38.52 billion by 2031, reflecting a compound annual growth rate of 9.77%. This sector comprises pharmaceutical formulations, including topical, oral, and parenteral therapies, developed to diagnose and manage conditions affecting the skin, hair, and nails. The market's growth is largely driven by the rising incidence of chronic skin diseases, such as psoriasis and atopic dermatitis, along with an aging demographic prone to dermatological issues. For instance, the National Eczema Association reported in 2025 that over 10% of the United States population had been diagnosed with some form of eczema, highlighting the critical need for effective therapeutic interventions and the broadening scope of the global market.

Despite this positive outlook, the market faces significant hurdles due to the high costs associated with advanced biologic therapies and novel small molecule drugs. These premium pricing structures often lead to restricted patient access and reimbursement limitations, particularly in developing regions with tighter healthcare budgets. Additionally, rigorous regulatory approval protocols for new chemical entities can prolong market entry and escalate development expenses. Consequently, these financial and regulatory barriers pose serious obstacles that could hinder the widespread adoption of innovative treatments and slow the sector's overall expansion.

Market Driver

The increasing global prevalence of both chronic and acute skin disorders acts as a primary catalyst for market growth, requiring a greater volume of pharmaceutical interventions. With diagnosis rates climbing for conditions ranging from autoimmune diseases to skin malignancies, healthcare systems are compelled to prioritize effective therapeutics. According to the American Cancer Society's "Cancer Facts & Figures 2024," released in January 2024, an estimated 100,640 new cases of invasive melanoma were projected to be diagnosed in the United States within that year. This rising disease burden directly leads to higher prescription volumes for oncology-related dermatological drugs and drives the persistent need for innovative treatment modalities to handle complex patient requirements effectively.

Simultaneously, the competitive landscape is being reshaped by advancements in biologics, small molecules, and targeted therapies, which offer superior efficacy and safety compared to traditional systemic treatments. Pharmaceutical companies are actively broadening their portfolios with novel mechanisms of action, especially for refractory conditions like atopic dermatitis. As reported by Sanofi in February 2024 within their "Full Year 2023 Results," sales of Dupixent, a biologic for atopic dermatitis, reached €10.76 billion due to strong patient demand. Furthermore, the sector is supported by the thriving aesthetic segment; according to AbbVie in 2024, global net revenues for Botox Cosmetic totaled $2.68 billion for the full year 2023, confirming the significant economic contribution of cosmetic dermatology to the total market valuation.

Market Challenge

The substantial cost associated with advanced biologic therapies and novel small molecule drugs constitutes a major challenge hindering the expansion of the Global Dermatological Drugs Market. The premium pricing of these innovative treatments often exceeds the financial capacity of healthcare budgets, forcing payers to implement strict reimbursement restrictions such as step therapy and prior authorization. These cost-containment measures create significant barriers to patient access, effectively preventing a large segment of the eligible population from obtaining prescribed treatments. When coverage is unobtainable, the adoption rate of these high-value drugs slows, which directly limits revenue growth for manufacturers and stalls the sector's financial progress.

This trend of restricted accessibility is confirmed by recent industry data emphasizing the severity of coverage obstacles. In 2024, the National Eczema Association cited a study revealing that 44% of prescriptions for biologic therapies were either delayed or denied by insurers due to stringent coverage protocols. Such elevated denial rates significantly limit the market penetration of advanced formulations. Consequently, the market's inability to efficiently deliver these expensive but effective drugs to patients functions as a critical brake on the overall industry's trajectory.

Market Trends

The integration of artificial intelligence is fundamentally transforming the drug discovery landscape within the dermatological sector. Pharmaceutical companies are increasingly utilizing generative AI models to identify new therapeutic targets and optimize molecule design, thereby significantly reducing the time and capital required to bring new treatments to market. This technological shift is particularly vital for complex skin conditions where traditional screening methods have historically struggled to identify effective candidates. For instance, Almirall announced in a January 2024 press release titled "Almirall Announces Partnership With Microsoft" that it had established a three-year strategic collaboration to deploy generative AI and advanced analytics specifically to accelerate the discovery and development of innovative therapies for medical dermatology.

Concurrently, Janus kinase (JAK) inhibitors are rapidly emerging as a dominant therapeutic class, addressing significant unmet needs in immune-mediated skin diseases such as vitiligo and atopic dermatitis. Unlike broad-spectrum immunosuppressants, these small molecule therapies offer targeted modulation of cytokine pathways, providing high efficacy for patients who may not respond to conventional biologics. The commercial success of these formulations highlights their growing acceptance among prescribers and patients seeking non-steroidal alternatives for chronic conditions. According to Incyte's "2024 Third Quarter Financial Results" from October 2024, net product revenues for Opzelura, a topical JAK inhibitor, reached $139 million for the third quarter, marking a substantial 52% increase compared to the same period in the previous year.

Key Market Players

• AbbVie Inc.
• Pfizer Inc.
• Glaxo Smith Kline PLC
• Sun Pharmaceutical Industries Ltd
• Galderma SA
• Amgen Inc
• Johnson & Johnson Services, Inc.
• Novartis AG
• Almirall, S.A
• Eli Lilly and Company
• Bausch Health Companies Inc.

Report Scope

In this report, the Global Dermatological Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermatological Drugs Market, By Therapy

• Acne
• Psoriasis
• Rosacea
• Alopecia
• Others

Dermatological Drugs Market, By Type

• Prescription
• Over-the-counter

Dermatological Drugs Market, By Route of Administration

• Topical
• Oral
• Parenteral

Dermatological Drugs Market, By Drug Class

• Corticosteroids
• Retinoids
• Antibiotics
• Antifungals
• Calcineurin Inhibitors
• Others

Dermatological Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Dermatological Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermatological Drugs Market.

Available Customizations:

Global Dermatological Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dermatological Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Acne, Psoriasis, Rosacea, Alopecia, Others)
  • 5.2.2. By Type (Prescription, Over-the-counter)
  • 5.2.3. By Route of Administration (Topical, Oral, Parenteral)
  • 5.2.4. By Drug Class (Corticosteroids, Retinoids, Antibiotics, Antifungals, Calcineurin Inhibitors, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Dermatological Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Drug Class
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dermatological Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Drug Class
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Dermatological Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Drug Class
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Dermatological Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Drug Class
      • 6.3.3.2.5. By Distribution Channel

7. Europe Dermatological Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Drug Class
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dermatological Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Drug Class
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. France Dermatological Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Drug Class
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. United Kingdom Dermatological Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Drug Class
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. Italy Dermatological Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Drug Class
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Dermatological Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Drug Class
      • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Dermatological Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Drug Class
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dermatological Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Drug Class
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Dermatological Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Drug Class
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Dermatological Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Drug Class
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Dermatological Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Drug Class
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Dermatological Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Drug Class
      • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Dermatological Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Drug Class
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dermatological Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Drug Class
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. UAE Dermatological Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Drug Class
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. South Africa Dermatological Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Drug Class
      • 9.3.3.2.5. By Distribution Channel

10. South America Dermatological Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Drug Class
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dermatological Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Drug Class
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Colombia Dermatological Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Drug Class
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Argentina Dermatological Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Drug Class
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dermatological Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Glaxo Smith Kline PLC
• 15.4. Sun Pharmaceutical Industries Ltd
• 15.5. Galderma SA
• 15.6. Amgen Inc
• 15.7. Johnson & Johnson Services, Inc.
• 15.8. Novartis AG
• 15.9. Almirall, S.A
• 15.10. Eli Lilly and Company
• 15.11. Bausch Health Companies Inc.

16. Strategic Recommendations

17. About Us & Disclaimer